Karen I. Sweiss
Clinical Assistant Professor, Pharmacy Practice
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
PDAT 9: Hematology/Oncology (PHAR 509), 1/9/2023 – 4/28/2023
Colloquium Lecture Series (PSCI 425), 8/22/2022 – 12/2/2022
Colloquium Lecture Series (PSCI 425), 8/22/2022 – 12/2/2022
PDAT 4: Immunology/Respiratory (PHAR 504), 8/22/2022 – 12/2/2022
PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PDAT 9: Hematology/Oncology (PHAR 509), 1/11/2021 – 4/30/2021
PHR 5617 Pharmacotherapeutic II, 4/23/2020 – 4/23/2020
PDAT 9: Hematology/Oncology (PHAR 509), 1/13/2020 – 5/1/2020
Selected Grants
Personalizing DNA damage in Multiple Myeloma, Emory University., 3/5/2021 - 6/30/2024, Obligated Amount: $89816; Anticipated Amount: $214655
OP-110 - An Expanded Access Program (EAP) Protocol for Melphalan Flufenamide ("melflufen") in Combination with Dexamethasone in Patients with Triple Class Refractory (TCR) Multiple Myeloma (MM)., Oncopeptides., 11/9/2020 - 11/8/2021, Obligated Amount: $152875; Anticipated Amount: $152875
Increasing the cure fraction in myeloma- a novel strategy to personalize melphalan dosing and overcome DNA repair-mediated resistance, UIC College of Pharmacy., 8/1/2020 - 7/31/2021, Obligated Amount: $25000; No Anticipated Amount Set
Pilot Study to Develop and Test a Multiplex Assay for CYP450 Phenotyping in Multiple Myeloma Patients Receiving Bortezomib, Hematology Oncology Pharmacy Association (HOPA)., 3/1/2020 - 7/28/2023, Obligated Amount: $85283; Anticipated Amount: $85283
Phase Ib study of the safety and efficacy of Omacetaxine and Venetoclax in patients with relapsed or refractory MDS/AML (VEN-OM), University of Illinois Cancer Center., 11/1/2019 - 7/1/2020, No Obligated Amount Set; No Anticipated Amount Set
Increasing the Cure Fraction in Myeloma: A Novel Strategy to Personalize Melphalan Dosing and Overcome DNA Repair-Mediated Resistance, Gateway for Cancer Research., Date Not Set - Present, No Obligated Amount Set; Anticipated Amount: $350000
AUC-based transplant in myeloma, University of Illinois Cancer Center., Date Not Set - Present, No Obligated Amount Set; Anticipated Amount: $40000
Selected Publications
Sweiss, Karen, Guo, Janet, Kim, Kyeongmin, Schecter, Jordan M, Sheng, Christina Y, Song, Dawei, Xu, Xiaoying, Su, Yaming, Wang, Weirong, Madduri, Deepu, Jackson, Carolyn C, Zudaire, Enrique, Yeh, Tzu-min, Roccia, Tito, Geng, Dong, Pacaud, Lida, Sborov, Douglas W, Phelps, Mitch A, Hofmeister, Craig C. (2023). 544 An Exploratory Analysis on the Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Who Received BCMA CAR-T Therapy in the Cartitude-1 Study. Transplantation and Cellular Therapy, 29, (2), s407-s408. doi:10.1016/s2666-6367(23)00612-7.
Sweiss, Karen, Guo, Janet, Kim, Kyeongmin, Hill, Kasey, Abbott, Nicole, Irby, Donald, Quigley, John, Rondelli, Damiano, Harvey, R Donald, Nooka, Ajay, Dhodapkar, Madhav Vishnu, Kaufman, Jonathan L, Joseph, Nisha, Lonial, Sagar, Sborov, Douglas W, Phelps, Mitch A, Hofmeister, Craig C. (2023). 217 Phase 1 Trial of AUC-Targeted Melphalan in Myeloma Patients Undergoing Autologous Transplant (The MyMel Study). Transplantation and Cellular Therapy, 29, (2), s168-s169. doi:10.1016/s2666-6367(23)00286-5.
Cruz, Calixto Hernández, de la Campa, Jesus Diego, del Castillo Carrillo, Concepcion, Llauger, Kali Cepero, Ramirez, Ibis K Pardo, García, Aliette García, Jiménez, Oliday Ríos, Fraga, Yusaima Rodriguez, Perurena, Jorge Munio, Rosales, Carlos Perez, Sweiss, Karen, Rodriguez, Ana Avila, Maahs, Lucas, Rondelli, Damiano, Uria, Jose Carnot. (2023). 400 Challenges and Results of Haploidentical Stem Cell Transplantation for Adult Patients in Cuba. Transplantation and Cellular Therapy, 29, (2), s302-s303. doi:10.1016/s2666-6367(23)00469-4.
Rodriguez, Ana Avila, Quigley, John, Sweiss, Jaleel, Kurzweil, Kaily, Sborov, Douglas, Sharp, Lisa K, Calip, Gregory, Maahs, Lucas, Uzoka, Chukwuemeka, Ilo, Elizabeth, Wolf, Elliot, Rondelli, Damiano, Hofmeister, Craig C, Sweiss, Karen. (2023). 51 Chronic Opioid Use Is Associated with Inferior Survival in Myeloma Patients Undergoing Autologous Transplant. Transplantation and Cellular Therapy, 29, (2), s44. doi:10.1016/s2666-6367(23)00120-3.
Maahs, Lucas, Sweiss, Karen, Uzoka, Chukwuemeka, Mahmud, Nadim, Chen, Zhengjia, Xu, Ziqiao, Avila, Ana Maria, Galvez, Carlos, Koshy, Matthew, Rondelli, Damiano. (2023). 485 High Dose Total Marrow Irradiation (TMI) Does Not Increase the Risk of Long-Term Toxicity to Myeloablative Fludarabine/Busulfan Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). Transplantation and Cellular Therapy, 29, (2), s364-s365. doi:10.1016/s2666-6367(23)00553-5.
Lin, Y, Park, Y, Khanal, A, Campbell-Lee, S, Liu, L, Chen, Z, Patel, P, Vidanovic, V, Sweiss, K, Irene, G, Peace, D, Rondelli, D, Mahmud, N. (2022). A comparison of four leukapheresis methods to harvest an optimal dose of CD34+ cells: A single center experience. European Journal of Haematology, 109, (6), 711-718. doi:10.1111/ejh.13856.
Sweiss, Karen, Patel, Pritesh, Guo, Janet, Kim, Kyeongmin, Schecter, Jordan M, Sheng, Christina Y, Song, Dawei, Xu, Xiaoying, Su, Yaming, Wang, Weirong, Madduri, Deepu, Jackson, Carolyn C, Zudaire, Enrique, Yeh, Tzu-min, Roccia, Tito, Geng, Dong, Pacaud, Lida, Sborov, Douglas W, Phelps, Mitch A, Hofmeister, Craig C. (2022). Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1. Blood, 140, (Supplement 1), 4323-4324. doi:10.1182/blood-2022-159501.
Avila, Ana Maria, Arain, Saad, Sweiss, Karen, Patel, Pritesh, Houshyar, Samin, Calip, Gregory S, Khan, Irum, Rubinstein, Paul G, Uzoka, Chukwuemeka, Quigley, John G. (2022). A Phase Ib Study of the Safety and Efficacy of Venetoclax When Combined with Escalating Doses of Omacetaxine in Patients with Relapsed/Refractory Acute Myeloid Leukemia Failing Treatment with Venetoclax-Containing Regimens (VEN-OM). Blood, 140, (Supplement 1), 11774-11775. doi:10.1182/blood-2022-165565.
Arain, Saad, Avila, Ana Maria, Christian, Sonia, Patel, Pritesh, Sweiss, Karen, Parkin, Brian, Saraf, Santosh L, Rubinstein, Paul G, Calip, Gregory S, Quigley, John G. (2022). Updated Analyses: Safety and Efficacy of Gemtuzumab Ozogamicin and Venetoclax in Patients with Relapsed or Refractory CD33+ Acute Myeloid Leukemia: A Phase Ib/II Study. Blood, 140, (Supplement 1), 11725-11726. doi:10.1182/blood-2022-165615.
Notable Honors
2020, 2020 Best Oral Abstract Award, BMT Pharmacist Conference at the 2020 Transplantation and Cellular Therapy (TCT) Conference
Selected Presentations
Sweiss, karen. (2021 February 01). Comparison of Individualized Versus MAP- Bayesian Predicted AUC of Busulfan in FluBu4 Treated Patients Undergoing Allogeneic Transplant. 2021 Transplantation & Cellular Therapy Meetings of ASTCT and CIDMTR.